Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register
M.H. Otten(Erasmus University Rotterdam), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Sebastiaan J. Vastert(Utrecht University), Sylvia Kamphuis(Erasmus MC - Sophia Children’s Hospital), Joost F. Swart(Trinity College Dublin), Marinka Twilt(University of Calgary), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), Koert M. Dolman(Reade), Y. Koopman-Keemink(Juliana Kinderziekenhuis), J. Merlijn van den Berg(Boston Children's Hospital), Femke H. M. Prince(Brigham and Women's Hospital), Wineke Armbrust, Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), Philomine A van Pelt(Erasmus MC - Sophia Children’s Hospital), Janneke Anink(Boston Children's Hospital)
Cited by 58
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
|The Lancet Child & Adolescent Health|2019|214